1. Efficacy of a novel lumen-apposing metal stent for the treatment of symptomatic pancreatic pseudocysts (with video)
- Author
-
Tae Jun Song, Sang Soo Lee, Hyun Jong Choi, Jong Ho Moon, Seong Hun Kim, Kwang Hyuck Lee, Se Woo Park, Jong Kyun Lee, Yun Nah Lee, Seung Ok Lee, and Chang Min Cho
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pancreatic pseudocyst ,medicine.medical_treatment ,Lumen (anatomy) ,Endosonography ,Cohort Studies ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Pancreatic Pseudocyst ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Endoscopy, Digestive System ,Prospective Studies ,Prospective cohort study ,Adverse effect ,Aged ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,Stent ,Equipment Design ,Middle Aged ,medicine.disease ,digestive system diseases ,Endoscopy ,Surgery ,Clinical trial ,Surgery, Computer-Assisted ,Metals ,030220 oncology & carcinogenesis ,Drainage ,Female ,Stents ,030211 gastroenterology & hepatology ,business ,Cohort study - Abstract
Background and Aims Recently, a newly designed lumen-apposing metal stent (LAMS) with a conventional delivery system was developed. The purpose of this study was to evaluate the effectiveness and safety of a newly designed LAMS for EUS-guided drainage to treat symptomatic pancreatic pseudocysts. Methods This prospective multicenter cohort study included 34 patients with symptomatic pancreatic pseudocysts from 2016 to 2017. The patients underwent EUS-guided drainage with the newly designed LAMS (Niti-S SPAXUS; Taewoong Medical Co, Ltd, Ilsan, South Korea). Effectiveness outcome measurements included technical success rate, clinical success rate, successful stent removal rate, and procedural time. Safety outcome measurements included procedure and/or stent-related adverse events (AEs) and overall AEs. Patients were prospectively followed, and consecutive data were collected at discharge, at stent removal, and 20 days after stent removal. Results Thirty-four patients (mean age 51.7 ± 13.3 years, 26 men) were enrolled. The mean pseudocyst size was 9.23 ± 3.54 cm. The technical success rate was 97.1% (33/34). The clinical success rate was 94.1% (32/34). All stents were successfully removed. The mean procedural time from needle puncture to stent deployment was 10.3 ± 5.7 minutes. Four patients (11.8%) experienced procedure and/or stent-related AEs, including stent maldeployment (n = 1) and pseudocyst infection (n = 3). All patients completely recovered from the AEs. Bleeding caused by the stent or buried LAMS syndrome was not observed. No unplanned endoscopic procedures were required. Conclusions This study showed that EUS-guided drainage using the newly designed LAMS is technically feasible and effective for the treatment of symptomatic pancreatic pseudocysts. (Clinical trial registration number: NCT02730663.)
- Published
- 2019
- Full Text
- View/download PDF